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Summary The collagen crosslinks, pyridinoline and deoxypyridinoline, are recently described markers of the
rate of bone resorption. The urinary excretion of these compounds, expressed as a ratio to urinary creatinine,
has been measured using ion-pair reversed phase high-performance liquid chromatography in 20 patients
receiving oral pamidronate for bone metastases from breast cancer.
Before treatment the ratio of pyridinoline and deoxypyridinoline to creatinine in urine (UPCR and UdPCR
respectively) were each above normal in 16/20 (80%) patients. Urinary calcium excretion (UCCR) was
elevated in 15/20 (75%). There was a strong correlation between UPCR and UdPCR, but neither of the
crosslink measurements correlated well with UCCR. Urinary excretion of all three indices of bone resorption
fell significantly during pamidronate treatment. The median values after 4 weeks treatment were 63% of
baseline for UPCR, 45% for UdPCR and 26% for UCCR.
From this preliminary study urinary pyridinoline and deoxypyridinoline excretion appear to be promising
markers of bone resorption in advanced malignancy. Their role in response assessment and the advantages
over UCCR measurements merit further study.
Breast cancer commonly causes destructive lytic bone meta-
stases characterised by an accelerated rate of bone resorp-
tion. Several biochemical markers of bone metabolism have
been studied as indicators of bone response (Hortobagyi et
al., 1984; Coleman et al., 1988a). These have included
urinary calcium (Campbell et al., 1983) and hydroxyproline
excretion (Blomqvist et al., 1987) which are influenced by the
rate of bone resorption. However, they have significant
limitations for routine use in response assessment. Firstly,
urinary calcium excretion reflects the net difference in the
rate of bone resorption and formation. Although typically
increased in breast cancer, it may be normal, and therefore
probably unhelpful, in patients with predominantly sclerotic
metastatic bone disease. Secondly, hydroxyproline excretion
is not specific for bone collagen resorption and profoundly
influenced by diet, collagen synthesis, complement activation
and particularly in malignancy, soft tissue destruction by
extraskeletal metastases. Levels may therefore reflect changes
in these confounding factors rather than changes in bone
metabolism.
Recently, a new class of potential markers of bone turn-
over have been identified (Eyre & Oguchi, 1980; Beardsworth
et al., 1990). These are the crosslinking amino acids of col-
lagen, pyridinoline (also known as hydroxylysylpyridinoline),
and deoxypyridinoline (also known as lysylpyridinoline). The
urinary excretion of pyridinoline and deoxypyridinoline can
now be reliably measured (James et al., 1990) and are specific
measures of the rate of bone resorption (Uebelhart et al.,
1990).
Elevated levels of pyridinoline and deoxypyridinoline com-
pared with normal subjects have been reported in metabolic
bone disease (Uebelhart et al., 1990 and 1991) and in a small
series ofpatients with bone metastases (Paterson et al., 1991).
However, to our knowledge there have been no reports of the
effects of treatment for bone metastases on cross-link excre-
tion. In this study we have measured pyridinoline and deoxy-
pyridinoline in patients with bone metastases from breast
cancer before and during treatment with oral pamidronate.
Methods
Twenty women with bone metastases from breast cancer
were recruited as part of a multicentre tolerability and
efficacy study of a new enteric-coated micropellet of pamid-
ronate developed by Ciba Geigy Ltd, Basle. Patients had
either radiographic evidence of progressive bone disease, or
apparently stable disease for at least 6 months, but with
symptoms which justified a treatment change. Patients were
randomly allocated to receive oral pamidronate at one of
three dose levels, 75 mg daily (n = 7), 150 mg daily (n = 5) or
300 mg daily (n = 8) for 4 weeks. Patients received no other
systemic therapy for breast cancer except for those already
on endocrine treatment who continued with this to prevent
the confounding effect of a withdrawal response. After 4
weeks the study period ended and pamidronate was con-
tinued with or without other systemic treatments as appropri-
ate. For the purposes of this study the data are confined to
the 4 week study period.
Patients were evaluated before treatment and at weekly
intervals for 4 weeks during treatment. Blood was taken at
each visit for routine haematology and biochemistry and the
tolerability of oral pamidronate recorded (to be published
elsewhere). On the morning of each assessment, patients
collected the second early morning fasting sample of urine
voided. The urine was acidified with 1.5 ml of normal (3%)
hydrochloric acid for every 20 ml of urine and stored at
-200 for subsequent measurement of pyridinoline, deoxy-
pyridinoline, calcium and creatinine.
The HPLC method for measurements of pyridinoline and
deoxypyridinoline has been described in detail elsewhere
(James et al., 1990). Briefly, the assay used ion-pair reversed-
phase high performance liquid chromatography (HPLC) in
the presence of I-octanesulphonic acid (OSA). Pyridinoline
and deoxypyridinoline were separated on a 5 tm ODS tech-
sphere column (100 mm x 4.6 mm I.D.) [HPLC Teclhnologies,
Macclesfield]. The column was eluted with mobile phase
consisting of 25 mM sodium formate, 5 mM OSA and 1 mM
ethylenediaminetetraacetic acid (EDTA) adjusted to pH 3.25,
containing 17.5% (v/v) methanol at 1.25 ml min'. Com-
pounds were detected by their natural fluorescence (xenon
lamp; excitation wavelength 290 nm, emission wavelength
400 nm) using a Jasco 821SP fluorimeter. The intra-assay
coefficients of variation were 7.65% for pyridincline and
9.07% for deoxypyridinoline. The limit of detection was
200fmol. Sample results were expressed as a ratio of
pyridinoline or deoxypyridinoline (in nmols 1-1) to creatinine
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(in mmols 1') (UPCR and UdPCR respectively). The upper
limits of normal in adult women for UPCR and UdPCR
vary with age but using this technique were <30 and <10
(unpublished data). These are slightly lower than reported
measurements on fasting early morning samples from post-
menopausal women (Uebelhart et al., 1991) but in accor-
dance with the previously published normal ranges for
measurements of UPCR and UdPCR performed on 24 h
urine collections in post-menopausal women (Uebelhart et
al., 1990) and women aged 30-70 (Beardsworth et al., 1990).
Urinary calcium (jimol 1') was measured using the
cresolphthalein-complexone method and a colourimetric
assay (Ciba-Corning Diagnostics, USA). Urinary creatinine
(mmolI1) was measured using an enzymatic determination
with creatininase/creatikinase (WAKO chemicals, Japan).
The urinary calcium and creatinine were then expressed as a
ratio (Peacock et al., 1969). The upper limit of normal for
the urinary calcium/creatinine ratio was taken as 300.
Standard statistical tests for calculation of correlation
coefficients and P values were used. The paired students t-test
was used to study differences between initial values of
UCCR, UPCR and UdPCR and those during treatment
(Armitage, 1971).
Results
Pretreatment levels of UPCR and UdPCR were each elevated
above the normal range in 16/20 (80%) of patients. The
range of values for UPCR was 16-401 (median 71) and for
UdPCR 2.1-95 (median 15). The UCCR was elevated in
15/20 (75%) with a range ofvalues of40-1,390 (median 600)
(Figure 1). Only one patient had normal values of all three
markers of bone resorption. The correlation between UPCR
and UdPCR was strong (r = 0.96, P = <0.001) but neither
of the crosslinks showed a significant correlation with UCCR
(r=0.29, P =0.5 for UPCR, r=0.20, P=>0.5 for
UdPCR).
During treatment with pamidronate, as bone resorption
was inhibited, urinary excretion of both collagen crosslinks
and calcium reduced. After 4 weeks treatment the median
values (expressed as a percentage of the pretreatment level)
were 63% for UPCR, 45% for UdPCR and 26% for UCCR.
Patients with elevated pretreatment levels showed significant
falls in UCCR (P = <0.001) in 14/15 (93%), UPCR
(P = <0.01) in 13/16 (81%) and UdPCR (P = <0.001) in
14/16 (88%) patients respectively (Figure 2). Changes in the
few patients with normal baseline values were variable and
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Figure 2 Changes after 4 weeks treatment with oral pamidronate in UCCR (top, n = 15), UPCR (middle, n = 16) and UdPCR
(bottom, n = 16) in patients with initially elevated values. Values
expressed as a percentage of baseline.
difficult to interpret. The two patients who showed an in-
crease in UPCR and UdPCR during treatment had a fall in
UCCR. Both UPCR and UdPCR were normal in the patient who showed a rise in UCCR. A wide range of pre and post
treatment values were seen, but based on the limited statis-
tical power of such small groups, the reduction in pyridi- noline crosslink excretion did not appear to be related to the
daily dose of pamidronate.
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Figure 1 Urinary excretion of calcium in jtmol (UCCR),
pyridinoline in nmol l-l (UPCR) and deoxypyridinoline in
nmol I -I (UdPCR) before starting pamidronate (n = 20). Ex-
pressed as a ratio to creatinine excretion (mmol' 1). The upper
limit of normal for the ratios are as indicated.
In recent years there has been a considerable interest in
metastatic bone disease. Our understanding of the
pathophysiological processes involved and the emergence of
new treatments has prompted a search for reliable, repro- ducible and convenient markers of response. These are
needed to complement plain radiography which can be diffi-
cult to interpret and which show structural disturbances that
only slowly and unreliably reflect changes in the metastases
and their effects on bone metabolism. Biochemical monitor-
ing can predict response to treatment (Blomqvist et al., 1987; Coleman et al., 1988), but more specific markers of bone
resorption and formation should improve on the results
reported so far.
Studies of collagen structure have revealed that the col-
lagen matrix is held together by intermolecular non-reducible
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crosslinking amino acids. In hard connective tissues such as
bone, dentine and cartilage the predominant crosslinks are
the naturally fluorescent pyridinium compounds pyridinoline,
and deoxypyridinoline (Eyre & Oguchi, 1980). Pyridinoline is
the major component in all these tissues while deoxy-
pyridinoline is largely confined to bone and dentine where it
comprises 21-22% of collagen crosslinks.
Both pyridinoline and deoxypyridinoline are almost com-
pletely excreted during collagen degradation (Segrest, 1982),
are unaffected by diet, and found in free and conjugated
forms in urine at levels of approximately 1 per 15,000 amino
acid residues. Several methods have been developed for
quantification of pyridinoline including cation-exchange
chromatography (Fujimoto et al., 1983), an enzyme-linked
immuno absorbent assay (ELISA) directed against pyridi-
noline and deoxypyridinoline which can therefore not be
measured separately by this technique (Robins, 1982), reverse
phase HPLC (Black et al., 1988) and, as used in this study a
modified HPLC technique allowing rapid assay of both
pyridinoline and deoxypyridinoline (James et al., 1990).
Elevated levels of UPCR and UdPCR compared with nor-
mal subjects have been reported in Paget's disease of bone,
hyperparathyroidism and osteoporosis. The raised levels
reflect the increased rate of bone resorption associated with
these conditions. Levels of UPCR and UdPCR then fall as
resorption is inhibited following treatment with for example,
pamidronate for Paget's disease (Uebelhart et al., 1990) or
hormone replacement therapy for osteoporosis (Uebelhart et
al., 1991). In this study the UPCR and UdPCR were elevated
in 80% of our patients with metastatic bone disease. These
results are similar to the findings of Paterson et al. (1991)
who observed increased crosslinks excretion in eight out of
ten patients with bone metastases.
Pamidronate is a potent inhibitor of osteoclast activity and
the treatment of choice for hypercalcaemia of malignancy
(Ralston et al., 1989). Long-term administration of pami-
dronate has consistently shown a reduction in morbidity
from bone metastases (van Holten-Verzantvoort et al., 1987)
and, in some patients, healing of lytic bone metastases has
been observed (Coleman et al., 1988b; Dodwell & Howell,
1991). In this study, testing a new oral formulation of pami-
dronate, the rate of bone resorption was increased in the
majority ofpatients before treatment and then slowed, with a
few exceptions, during treatment. UPCR and UdPCR did
not correlate well with calcium excretion suggesting they
reflect different facets of bone destruction. In addition, the
fall in UPCR and UdPCR excretion during oral pamidronate
treatment although significant, was of a smaller magnitude
than the suppression of calcium excretion.
Previous trials with intravenous pamidronate have shown
an initial fall in urinary calcium excretion in all patients.
However, in some patients the calcium excretion rises again
after the initial fall and, only a subset of patients achieving a
normal calcium excretion which is maintained over several
months who appear to benefit either symptomatically or radio-
logically (Coleman et al., 1988b; Dodwell et al., 1990). The
explanations for both the unmaintained effect ofpamidronate
and a lack of response in some patients despite apparent
inhibition of bone resorption are not known. Further studies
are planned which will incorporate measurements of UPCR
and UdPCR in the hope that these more specific markers of
bone resorption will identify those patients who will benefit
most from bisphosphonate treatment.
In conclusion, our preliminary results indicate that urinary
excretion of pyridinoline and deoxypyridinoline is raised in
patients with bone metastases and falls as bone resorption is
inhibited by the bisphosphonate pamidronate. The value of
these markers in a larger cohort of patients compared with
an age-matched control population and their role in assess-
ment of response in bone to endocrine and cytotoxic
treatments is now being studied.
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